









Mercado
/
Acciones
/
nasdaq-bhvn
/

Biohaven Ltd

BHVN

17.390USD

-0.720-3.98%

Cierre 10/30, 16:00（ET）Cotizaciones retrasadas 15 min

1.84BCap. mercado

PérdidaP/E TTM



Biohaven Ltd

17.390

-0.720-3.98%

Descripción general Compañía Finanzas Análisis

Descripción general

Compañía

Finanzas

Análisis

Más Datos de Biohaven Ltd Compañía

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.

Información de Biohaven Ltd



Símbolo de cotizaciónBHVN

Nombre de la empresaBiohaven Ltd

Fecha de salida a bolsaSep 23, 2022

Director ejecutivoDr. Vlad Coric, M.D.

Número de empleados256

Tipo de seguridadOrdinary Share

Fin del año fiscalSep 23

Dirección215 Church Street

CiudadNEW HAVEN

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal06510

Teléfono12034040410

Sitio Webhttps://www.biohaven.com/

Símbolo de cotizaciónBHVN

Fecha de salida a bolsaSep 23, 2022

Director ejecutivoDr. Vlad Coric, M.D.

Ejecutivos de Biohaven Ltd



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Gregory Hugh (Greg) Bailey, M.D.

Independent Director

1.62M

Mr. Matthew (Matt) Buten

Chief Financial Officer

193.45K

+0.39%

Dr. Bruce Car, Ph.D.

Chief Scientific Officer

34.80K

+757.19%

Ms. Julia Paige Gregory

Independent Director

25.66K

Mr. Kishan (Kishen) Mehta

Director

22.66K

Mr. Michael Thomas (Mike) Heffernan

Lead Independent Director

15.18K

Mr. Robert J. Hugin

Independent Director

12.96K

Dr. Irina Antonijevic, M.D., Ph.D.

Independent Director

Mr. John W. Childs

Independent Director

Dr. Vlad Coric, M.D.

Chairman of the Board, Chief Executive Officer

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Gregory Hugh (Greg) Bailey, M.D.

Independent Director

1.62M

Mr. Matthew (Matt) Buten

Chief Financial Officer

193.45K

+0.39%

Dr. Bruce Car, Ph.D.

Chief Scientific Officer

34.80K

+757.19%

Ms. Julia Paige Gregory

Independent Director

25.66K

Mr. Kishan (Kishen) Mehta

Director

22.66K

Mr. Michael Thomas (Mike) Heffernan

Lead Independent Director

15.18K

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: sáb., 16 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

1919 Investment Counsel, LLC

6.23%

Childs John W

6.15%

BlackRock Institutional Trust Company, N.A.

6.08%

Suvretta Capital Management, LLC

5.31%

Janus Henderson Investors

4.78%

Otro

71.44%

Accionistas

Proporción

1919 Investment Counsel, LLC

6.23%

Childs John W

6.15%

BlackRock Institutional Trust Company, N.A.

6.08%

Suvretta Capital Management, LLC

5.31%

Janus Henderson Investors

4.78%

Otro

71.44%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

28.64%

Investment Advisor/Hedge Fund

25.57%

Hedge Fund

16.33%

Individual Investor

11.13%

Research Firm

3.53%

Venture Capital

1.11%

Sovereign Wealth Fund

0.85%

Corporation

0.48%

Pension Fund

0.46%

Otro

11.89%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

557

87.60M

82.81%

-13.24M

2025Q2

561

102.09M

99.98%

-11.50M

2025Q1

573

104.91M

102.74%

-8.33M

2024Q4

560

105.43M

103.87%

-2.30M

2024Q3

544

99.41M

101.90%

-4.10M

2024Q2

514

95.57M

103.25%

+3.60M

2024Q1

494

86.58M

104.39%

-3.45M

2023Q4

444

83.44M

104.38%

+4.72M

2023Q3

398

73.50M

107.61%

-2.29M

2023Q2

372

72.49M

106.13%

-7.40M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

1919 Investment Counsel, LLC

6.60M

6.23%

+2.50K

+0.04%

Jun 30, 2025

Childs John W

6.51M

6.15%

+351.58K

+5.71%

Mar 10, 2025

BlackRock Institutional Trust Company, N.A.

6.44M

6.08%

+113.23K

+1.79%

Jun 30, 2025

Suvretta Capital Management, LLC

5.62M

5.31%

Jun 30, 2025

Janus Henderson Investors

5.05M

4.78%

-1.38M

-21.51%

Jun 30, 2025

State Street Investment Management (US)

3.54M

3.34%

+115.81K

+3.38%

Jun 30, 2025

Coric (Vladimir)

3.18M

+26.57K

+0.84%

Mar 10, 2025

T. Rowe Price Associates, Inc.

3.08M

2.91%

+340.20K

+12.40%

Jun 30, 2025

The Vanguard Group, Inc.

9.23M

8.72%

+828.80K

+9.87%

Jun 30, 2025

Bellevue Asset Management AG

2.80M

2.65%

+762.00K

+37.34%

Jun 30, 2025

ETFs relacionados



Actualizado: lun., 6 de oct

Nombre

Proporción

iShares Neuroscience and Healthcare ETF

2.95%

Roundhill GLP-1 & Weight Loss ETF

1.88%

Simplify Health Care ETF

1.12%

Virtus LifeSci Biotech Clinical Trials ETF

0.77%

SPDR S&P Biotech ETF

0.45%

WisdomTree BioRevolution Fund

0.31%

Direxion Daily S&P Biotech Bull 3X Shares

0.27%

Inspire Small/Mid Cap ESG ETF

0.2%

JPMorgan Fundamental Data Science Small Core ETF

0.18%

iShares Biotechnology ETF

0.13%

iShares Neuroscience and Healthcare ETF

Proporción2.95%

Roundhill GLP-1 & Weight Loss ETF

Proporción1.88%

Simplify Health Care ETF

Proporción1.12%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción0.77%

SPDR S&P Biotech ETF

Proporción0.45%

WisdomTree BioRevolution Fund

Proporción0.31%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción0.27%

Inspire Small/Mid Cap ESG ETF

Proporción0.2%

JPMorgan Fundamental Data Science Small Core ETF

Proporción0.18%

iShares Biotechnology ETF

Proporción0.13%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

